Final results of a phase 3, randomized, open-label study of darbepoetin alfa 200 mcg every 2 weeks (Q2W) versus epoetin alfa 40,000 U weekly (QW) in patients with chemotherapy-induced anemia (CIA)

被引：0

作者：

Glaspy, J

Berg, R

Tomita, D

Rossi, G

Vadhan-Raj, S

机构：

[1] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA

[2] Amgen Inc, Thousand Oaks, CA 91320 USA

[3] MD Anderson Canc Ctr, Houston, TX USA

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期

关键词：

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：760S / 760S

页数：1

共 50 条

[1] Darbepoetin alfa (DA) 200 mcg every 2 weeks (Q2W) vs epoetin alfa (Epo) 40,000 U weekly (QW) in anemic patients (pts) receiving chemotherapy
Schwartzberg, L
Yee, L
Senecal, F
Charu, V
Tomita, D
Rossi, G
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 744S - 744S
[2] Darbepoetin alfa 200 mcg every 2 weeks (Q2W) and epoetin alfa 40,000 units every week (QW) in chemotherapy-induced anemia patients result in similar initial hemoglobin outcomes
Patton, J
Wallace, JF
VALUE IN HEALTH, 2003, 6 (03) : 228 - 228
[3] Comparable efficacy and safety of darbepoetin alfa 200 mcg every 2 weeks (Q2W) and epoetin alfa 40,000 U weekly (QW) in patients (pts) with breast cancer: results of a randomized comparison
Schwartzberg, LS
Lee, LK
Charu, V
Tomita, D
Rossi, G
Senecal, FM
BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S230 - S230
[4] Early results of a head-to-head comparison of darbepoetin alfa 200 mcg given every 2 weeks (Q2W) and epoetin alfa 40,000 U given weekly (QW)
Schwartzberg, LS
Yee, LK
Senecal, FM
Charu, V
Yao, B
Mendes, E
Rossi, G
BLOOD, 2003, 102 (11) : 515A - 515A
[5] Epoetin alfa 40,000 U QW vs darbepoetin alfa 200 mcg Q2W in anemic cancer patients receiving chemotherapy: Preliminary results of a comparative trial.
Waltzman, RJ
Fesen, M
Justice, GR
Croot, C
Williams, D
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 767S - 767S
[6] Randomized comparison of epoetin alfa (40,000 U weekly) and darbepoetin alfa (200 μg every 2 weeks) in anemic patients with cancer receiving chemotherapy
Waltzman, R
Croot, C
Justice, GR
Fesen, MR
Charu, V
Williams, D
ONCOLOGIST, 2005, 10 (08): : 642 - 650
[7] Head-to-head comparison of epoetin alfa 40,000 U QW vs. darbepoetin alfa 200 mcg Q2W in anemic patients with cancer receiving chemotherapy: Preliminary results.
Jakubowski, AA
Hurria, A
Williams, D
BLOOD, 2003, 102 (11) : 170B - 170B
[8] Final hematologic results:: Epoetin alfa (EPO) 40,000 U QW vs darbepoetin alfa (DARB) 200 μg Q2W in anemic cancer patients (pts) receiving chemotherapy (CT).
Waltzman, RJ
Croot, C
Williams, D
JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 736S - 736S
[9] Using the MD Anderson Symptom Inventory (MDASI) to assess symptom burden and interference: Interim results of an open-label study of darbepoetin Alfa 200 mcg every 2 weeks (Q2W) for the treatment of chemotherapy-induced anemia (CIA).
Cleeland, C
Crawford, J
Lubeck, D
Tomita, D
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 745S - 745S
[10] Cost and effectiveness of darbepoetin ALFA administered every 3 weeks (Q3W DA) compared with weekly epoetin ALFA (QW EA) or epoetin beta (QW EB) in patients (PTS) with chemotherapy-induced anemia (CIA): A retrospective study
Coiffier, Bertrand
Schlag, Rudolf
Velasco, Amalia
Yao, Bin
Schupp, Marco
Demarteau, Nadia
Annemans, Lieven
ANNALS OF ONCOLOGY, 2006, 17 : 293 - 293

← 1 2 3 4 5 →